The prevalence of liver injury ranged from 14.8 to 55% in COVID-19 patients.93,131,132,268–271 The pooled prevalence of liver function abnormalities was 19%.272 In a cohort including 2273 SARS-CoV-2-infected patients, acute liver injury is common but generally mild.273 Liver function abnormalities mainly manifest as slightly elevation in levels of alanine aminotransferase (ALT), total bilirubin (TBIL), and gamma-glutamyl transpeptidase (GGT).274 Aspartate aminotransferase (AST)-dominant elevation may be earlier, more frequent and significant in patients with severe COVID-19. The gene discussed is GGTLC1; the disease is COVID-19.